Report on the Annual Meeting of the American Society for Radiation Oncology (ASTRO)
November 9, 2018
SRS/SBRT ‘Key Takeaways’ from the ASTRO Meeting by John SUH
The 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) was held in San Antonio from October 21-24, 2018. One of the plenary talks by Dr David Palma from the London Health Science Centre generated tremendous interest given its implication on the use of stereotactic radiation for oligometastatic patients. He presented the first randomized, phase II trial of stereotactic ablative radiotherapy (SABR) to conventional radiation therapy for oligometastatic patients. This study, SABR-COMET, enrolled 99 patients from four countries (Canada, Scotland, the Netherlands and Australia) with a wide range of tumors (most commonly breast, lung, colon or rectum, and prostate) that had metastasized to 1-3 new sites. Those who received SABR had median survival of 41 months compared to 28 months for the standard arm. In addition, the progression-free survival was doubled from 6 to 12 months. Although the side effects were higher in the SABR arm, the quality of life was similar for both arms. A follow-up study, SABR-COMET-10, will enroll patients with up to 10 metastatic lesions.
Chairman Radiation Oncology, Cleveland, USA